| This week's sponsor is Roquette. | |  | Roquette - The Biological Choice
Sole custody of our supply chain ensures a safe, secure and reliable supply of quality raw materials and excipients. Trust Roquette for all your biopharma needs. Learn more. |
Featured Story | | | Monday, May 22, 2017 Amgen and UCB's romosozumab trounced a comparator drug in a trial in osteoporosis, but there's a big catch: The therapy seems to cause side effects that will delay and could scupper its chances of reaching the market. |
|
|
| This week's sponsor is Precision for Medicine. | |  | Harmonizing biomarker data in clinical studies
Diverse assays. Multiple vendors. 1000s of biomarker data points in separate formats. See the tools pharma is using now to harmonize data and reduce time, costs and mitigate risks.
Get the free case study. |
Top Stories Monday, May 22, 2017 Celgene has posted some new late-stage data from its second pivotal test in multiple sclerosis for its $7.2 billion oral candidate ozanimod, showing it could beat out Biogen’s marketed MS med Avonex in reducing annualized relapse rates in a head-to-head, hitting its primary endpoint. Monday, May 22, 2017 Shire and drug partner Xenetic have released new data for their collab bleeding disorder drug SHP656 and the news isn’t good. Monday, May 22, 2017 With pressures to fast-track clinical development, the pharmaceutical industry recognizes the value of improving internal clinical data management processes. Learn how using comprehensive analytical capabilities helps to advance clinical trial execution. Monday, May 22, 2017 La Jolla Pharmaceutical has posted a full look at data from a phase 3 trial of its vasodilatory shock candidate LJPC-501. Key findings are in line with the earlier, positive top-line data drop but the picture becomes muddier beyond the primary endpoint, with the lack of improvement to mortality and total organ function raising doubts about whether LJPC-501 can win over physicians. Monday, May 22, 2017 Ablynx and Merck KGaA have moved their osteoarthritis candidate to the cusp of the clinic. Merck accepted the preclinical package for single-domain antibody ALX-1141, triggering a €15 million ($17 million) milestone payment to Ablynx and teeing it up to start clinical development. Monday, May 22, 2017 Perennial biotech investor and backer Takeda has signed its latest collaboration with Nektar Therapeutics that will see the pair work on combo cancer approaches with NKTR-214, a CD122-biased agonist, as well as five Takeda oncology compounds. Monday, May 22, 2017 Serendipity can play a key role in scientific discovery, and it certainly did for a group of neuroscientists at Brigham and Women's Hospital in Boston who were searching for clues to the development of multiple sclerosis when they found an antibody with cancer-fighting properties. Monday, May 22, 2017 Researchers have used data gathered by connected thermometers to predict the onset of an influenza outbreak. An analysis of data from users of the iThermometer wearable and companion app in China predicted the spike in the 2015-16 flu season one month before the country’s public health body. Monday, May 22, 2017 When Radius Health scored an early approval for its osteoporosis med Tymlos last month, industry watchers thought it wouldn't be long before the drug had to contend with another newcomer from Amgen. But now, Amgen says it’ll be a while before its drug hits the market—if ever. | | | Tim Mayleben, president and CEO of Esperion, has penned an unusual rebuttal to a recent report from an investment firm that had "misinterpretations or intentionally inaccurate statements regarding Esperion and bempedoic acid." CEO's blog Otsuka says its additional phase 3 data for tolvaptan in ADPKD saw positive results for its primary and key secondary endpoints versus placebo. Release PCI Biotech and RNAi biotech RXi Pharmaceuticals have extended their preclinical research collaboration first inked back in 2015. Statement | |
|
Resources Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Sponsored By: Veeva To thrive in a fiercely competitive market, life sciences companies need to set themselves apart by designing and executing the best trial and successfully deliver drugs to market first. Learn how a modern EDC can help. Sponsored By Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. | 
